El intersticio pulmonar y sus enfermedades en la infancia. Confusión diagnóstica en el recién nacido. Enfermedades genéticas del surfactante pulmonar. A propósito de un caso clínico: clínica, radiología, estudios y diagnóstico diferencial / The pulmonary interstitium and its diseases in childhood. Diagnostic confusion in the new born. Genetic diseases of pulmonary surfactant. About a clinical case: clinical, radiology, studies and differential diagnosis

Se presenta el caso clínico de un lactante fallecido a los siete meses de edad con cuadro intersticial persistente. Objetivos: describir detalladamente el camino diagnóstico; alertar sobre posibles confusiones en recién nacidos con diagnósticos más frecuentes; detallar los hallazgos clínicos, radiológicos y de anatomía patológica (consultas en el exterior). Metodología: sumatoria de estudios complejos para descartar causas más frecuentes de patología intersticial en el lactante; consultas radiológicas, de anatomía patológica y genética en el exterior del país. Resultado: con diagnóstico de PAP (proteinosis alveolar pulmonar) se encontró una duplicación de material genético a nivel de cromosoma X, correspondiente al gen CSF2RA (colony stimulating factor 2-subunidad a). Este gen codifica al receptor CSF2 cuya citoquina controla la producción, diferenciación y función de granulocitos/macrófagos. (AU)

A clinical case of a deceased seven month old infant presenting persistent interstitial lung compromise is presented. Objectives. Detailed description of the diagnostic pathway used; to alert about possible confusion with other ­ more frequent ­ pathologies in the new borninfant age; to present clinical, radiological, genetic and pathology findings (consultations abroad). Methodology. A complete description of complex studies to rule out other more frequent pathologies is presented together with radiological, pathological and genetic results from consultations abroad. Results. A diagnosis of PAP (pulmonary alveolar proteinosis) was confirmed with duplication of genetic material at CSF2RA gene (colony stimulating factor 2-subunit a). This gene codifies the CSF2 receptor whose cytokine controls production, differentiation and function of granulocytes/macrophages. (AU)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?

Purpose To evaluate the clinical outcome of a cohort of localized prostate cancer patients treate with 125-I permanent brachytherapy at the São José Hospital – CHLC, Lisbon. Materials and Methods A retrospective analysis was carried out on 429 patients with low and intermediate-risk of prostate adenocarcinoma, according to the recommendations of the EORTC, who underwent 125I brachytherapies in intraoperative dosimetry “real-time” system between September 2003 and September 2013. Results The mean follow-up was 71.98 months. Biochemical relapse of disease by rising PSA (Phoenix criterion) was observed in 18 patients (4.2%). Through the application of Kaplan-Meier survival curves in this sample, the rate of survival at 6 years without biochemical relapse was higher than 95%. By Iog rank test comparing biochemical relapse with initial PSA (15-10 and <10) and Gleason values (7 and <7), there was no statistical difference (P=0.830) of the initial PSA in the probability of developing biochemical relapse. In relation to Gleason score, it was noted a statistical difference (P<0.05), demonstrating that patients with Gleason 7 are more likely to develop biochemical relapse. Conclusions Brachytherapy as monotherapy is at present an effective choice in the treatment of localized prostate adenocarcinoma. Biochemical relapses are minimal. The initial PSA showed no statistically difference in the rate of relapses, unlike the value Gleason, where it was demonstrated that patients with Gleason 7 have a higher probability of biochemical relapse. Cases with PSA bounce should be controlled before starting a salvage treatment. .

CD14 C-159T polymorphism and its association with chronic lung diseases: A pilot study on isocyanate exposed population of Central India.

CONTEXT: CD14 functions as a multifunctional receptor for bacterial cell wall components including endotoxin and lipopolysaccharide and is likely to influence the cytokine profile and subsequent immunoglobulin E production in response to antigen/allergen contact in allergic phenotypes. AIMS: The present study was to investigate genetic polymorphism in CD14 gene - 159C/T, which may be one of the risk factor for increased prevalence of Chronic Lung Diseases in the Central India. SETTINGS AND DESIGN: Survivors of Methyl isocyanates toxicity in Bhopal still suffering from various respiratory ailments were examined. MATERIALS AND METHODS: Polymerase chain reaction-restriction fragment length polymorphism was performed to determine the polymorphism of C-159T. RESULTS: The genotype and allelic frequencies were in Hardy-Weinberg’s equilibrium. Prevalence of CC, CT, and TT were 5.5%, 22.2% and 9.25% respectively in asthmatics; 16.6%, 20.3% and 5.5% respectively in chronic obstructive pulmonary disease (COPD) patients and 5.5%, 14.8% and 1.85 respectively among interstitial lung disorder (ILD) patients; whereas the control cohort with no methyl isocyanate exposure displayed (CC, CT, and TT) cytosine, thymine as 2%, 1.6% and 2% respectively. Increased risk of Asthma among those carrying TT genotype and T allele (odds ratio [OR] =2.61 and 2.02 respectively). CONCLUSION: COPD risk significantly found among those with CC genotype and C allele (OR = 2.81 and 1.50 respectively), whereas ILD risk found significantly among CT genotype and C allele (OR = 1.75 and 1.40 respectively). Therefore, single nucleotide polymorphism (SNP) C-159T polymorphism in CD14 gene might be a risk factor for development of CLD in this population.

Avaliação da ultraestrutura e do movimento ciliar em crianças com pneumopatias crônicas e de repetição se diagnóstico definido / Evaluation of the ultrastructure and of the movement of cilia in children with chronic and repetition pneumopathies without a defined diagnosis

INTRODUÇÃO: A discinesia ciliar primária é uma doença genética que se caracteriza pela alteração da ultraestrutura e função do cílio móvel, com consequentes alterações do transporte mucociliar, causando infecções das vias aéreas superiores, inferiores e infertilidade. O diagnóstico, realizado por avaliação da ultraestrutura ou pesquisa de mutação genética, é feito mediante critérios de seleção de pacientes e testes de screening. Esta pesquisa avalia a ultraestrutura e frequência de batimento ciliar, propõe um modelo de investigação de discinesia ciliar primária, e caracteriza os pacientes diagnosticados. MÉTODO: Foi realizado um estudo transversal controlado entre janeiro de 2007 e julho de 2009, no Ambulatório de Pneumologia Pediátrica do Instituto da Criança. Foram selecionadas 28 crianças e adolescentes (6 meses a 19 anos, de ambos os sexos), de uma população de 75 crianças com pneumopatias crônicas e de repetição sem diagnóstico definido, que apresentavam ao menos um dos seguintes achados: bronquiectasia de causa desconhecida, doença de vias aéreas superiores com sintomatologia crônica, infecções pulmonares de repetição, dextrocardia e/ou situs inversus acompanhados de sintomas em vias aéreas superiores e/ou inferiores, e asma de difícil controle com sintomas em vias aéreas superiores e/ou inferiores. A presença de pneumopatias crônicas com diagnóstico definido foi utilizada como critério de exclusão por meio dos seguintes exames: dois testes do suor (exclusão de fibrose cística), tomografia computadorizada do tórax (suspeita de bronquiolite obliterante), dosagem de alfa-1 antitripsina (investigação de déficit de alfa-1 antitripsina), e exames de investigação das imunodeficiências mais frequentes (hemograma, dosagens de imunoglobulinas, contagem de linfócitos T e B, sorologias para avaliação da produção ativa de anticorpos, PPD e HIV). Foi desenvolvido um sistema medição da frequência de batimento ciliar, baseado em análise espectral. Dez adultos...

INTRODUCTION: Primary ciliary dyskinesia (PCD) is a genetic disorder of the ultrastructure and function of mobile cilia, with consequent impairment of mucociliary clearance, leading to upper and lower airways respiratory infection and infertility. The diagnosis, based on ultrastructure evaluation or genetic scan, is performed according to patient selection and screening tests. This research evaluates cilia ultrastructure and beat frequency, proposes a model for investigating primary ciliary dyskinesia, and characterizes the patients diagnosed.METHOD: A controlled and observational study was carried out at the Pediatric Pulmonology Ambulatory of the Instituto da Criança between January 2007 and July 2009. Twenty eight children and teenagers (ages between 6 months and 19 years) were selected, from a population of 75 patients with chronic and repetition pneumopathies without a defined diagnosis, which met at least one of the following inclusion criteria: bronchiectasis of unknown cause, upper respiratory disease with chronic symptoms, repetition pulmonary infections, dextrocardia and/or situs inversus with symptoms in upper and/or lower respiratory airways, and asthma of difficult control with symptoms in upper and/or lower respiratory airways. The presence of cronic pneumopathies with a defined diagnosis was used as exclusion criterion, based on the following exams: two sweat tests (cystic fibrosis exclusion), lung CT scan (bronchiolitis obliterans exclusion), seric levels of alpha-1 anti-trypsin (alpha-1 anti-trypsin deficit evaluation), and evaluation of more frequent immunodeficiency disorders (white blood cells, T and B lymphocytes levels, and sorology tests for humoral immunity, PPD and HIV). A cilia beat frequency measurement system was developed, based on spectral analysis. Ten healthy adult volunteers (ages greater than or equal to 17 years old, of both sexes), without an acute respiratory...

Associação entre os polimorfismos dos genes MBL2, TGF-beta1 e CD14 com a gravidade da doença pulmonar na fibrose cística / Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis

OBJETIVO: Verificar a correlação entre os polimorfismos dos genes MBL2, TGF-β1 e CD14 com a gravidade da doença pulmonar em pacientes com fibrose cística (FC), bem como correlacionar a presença dos alelos ΔF508 com a gravidade da doença naqueles pacientes. MÉTODOS: Estudo clínico-laboratorial, de corte transversal, com 105 pacientes fibrocísticos de um hospital universitário em 2005-2006. Foram analisados 202 doadores de sangue saudáveis como controles para a pesquisa dos polimorfismos no gene TGF-β1 e CD14. A análise de polimorfismos nos genes MBL2 e TGF-β1 no códon 10, posição +869, foi realizada pela técnica da PCR alelo-específica. A genotipagem do polimorfismo C-159T no gene CD14 foi realizada através de PCR e digestão enzimática. RESULTADOS: Dos 105 pacientes com FC avaliados, 67 apresentavam doença pulmonar grave segundo o escore de Shwachman. Os polimorfismos do gene MBL2 não foram associados com a gravidade da doença nos fibrocísticos. A análise do polimorfismo T869C no gene TGF-β1 mostrou somente uma associação entre o heterozigoto TC com doença pulmonar leve. Para o polimorfismo C-159T no gene CD14, obtivemos um predomínio de pacientes com o genótipo TT, mas não houve diferença significativa com relação à gravidade do quadro pulmonar. CONCLUSÕES: Houve associação entre o genótipo TC do polimorfismo T869C (TGF-β1) e o quadro pulmonar leve nos fibrocísticos. No gene CD14, o genótipo TT parece ser um fator de risco para o quadro pulmonar, mas não um fator modulador da gravidade. Não existiu associação entre pacientes homozigotos para a mutação ΔF508 e a gravidade do quadro pulmonar.

OBJECTIVE: To identify associations between genetic polymorphisms (in the MBL2, TGF-β1 and CD14 genes) and the severity of the lung disease in patients with cystic fibrosis (CF), as well as between the presence of ΔF508 alleles and lung disease severity in such patients. METHODS: This was a cross-sectional cohort study, based on clinical and laboratory data, involving 105 patients with CF treated at a university hospital in the 2005-2006 period. We included 202 healthy blood donors as controls for the determination of TGF-β1 and CD14 gene polymorphisms. Polymorphisms in the MBL2 and TGF-β1 genes at codon 10, position +869, were genotyped using the allele-specific PCR technique. The C-159T polymorphism in the CD14 gene was genotyped using PCR and enzymatic digestion. RESULTS: Of the 105 CF patients evaluated, 67 presented with severe lung disease according to the Shwachman score. The MBL2 gene polymorphisms were not associated with disease severity in the CF patients. Analysis of the T869C polymorphism in the TGF-β1 gene showed an association only between TC heterozygotes and mild pulmonary disease. Although patients presenting the TT genotype of the C159T polymorphism in the CD14 gene predominated, there was no significant difference regarding lung disease severity. CONCLUSIONS: There was an association between the TC genotype of the T869C polymorphism (TGF-β1) and mild pulmonary disease in CF patients. In the CD14 gene, the TT genotype seems to be a risk factor for pulmonary disease but is not a modulator of severity. We found no association between being a ΔF508 homozygote and presenting severe lung disease.